1, In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to RIKEN BRC is requested.<br>2, For use of the BIOLOGICAL RESOURCE by a for-profit organization, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR.<br>3, RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. C57BL/6N-Trp53<em1.1Rbrc> RIKEN BRC developed this strain by crossing a floxed Trp53 strain (RBRC09921) with a Cre strain. This was funded through the FY2016 AMED-NBRP fundamental technology upgrading program. C（3〜6か月） RBRC10197 条件を付加する。<br>1, 研究成果の公表にあたってRIKEN BRCへの謝辞の表明を必要とする。<br>2, 営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。<br>3, 利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 Cre/loxP system Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: CRISPR/Cas9 genome edited bioresources (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/Broad_MTA_J.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/Broad_MTA_E.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> <a href='https://brc.riken.jp/mus/pcr10197'>Genotyping protocol -PCR-</a> true Trp53 knockout mice in the C57BL/6N genetic background. A genomic region from Exon 2 to Exon 9 of the Trp53 was deleted. Phage P1 loxP site, mouse Trp53 genomic DNA C (3-6 months)